Rasi Bhadramani/iStock via Getty Images
Silence Therapeutics (NASDAQ:SLN) added ~9% premarket Tuesday after its Phase 2 trial for lead candidate zerlasiran (SLN360) succeeded in patients with a high risk of cardiovascular disease due to atherosclerotic plaque buildup.
Citing 36-week topline data from the trial, Silence (SLN